Damora Therapeutics, Inc. (NASDAQ: DMRA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 3.20% | Shs Outstand | 61.55M | Perf Week | -19.61% |
| Market Cap | 1.39B | Forward P/E | - | EPS next Y | -2.06 | Insider Trans | -0.01% | Shs Float | 41.22M | Perf Month | -30.36% |
| Enterprise Value | 858.49M | PEG | - | EPS next Q | -0.52 | Inst Own | - | Short Float | 10.02% | Perf Quarter | 6.41% |
| Income | -210.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 7.26 | Perf Half Y | 17.66% |
| Sales | 0.00 | P/B | 2.73 | EPS next Y | -3.01% | ROA | -48.35% | Short Interest | 4.13M | Perf YTD | -1.83% |
| Book/sh | 8.29 | P/C | 2.61 | EPS next 5Y | - | ROE | -82.56% | 52W High | 38.33 -41.06% | Perf Year | 692.63% |
| Cash/sh | 8.66 | P/FCF | - | EPS past 3/5Y | - | ROIC | -52.44% | 52W Low | 2.77 715.52% | Perf 3Y | 46.88% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 8.27% 6.63% | Perf 5Y | -79.46% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | 64.31% | Oper. Margin | 0.00% | ATR (14) | 1.99 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 19.73 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 30.28 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 19.73 | EPS Q/Q | 85.00% | SMA20 | -18.99% | Beta | 1.40 | Target Price | 43.75 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -22.89% | Rel Volume | 5.20 | Prev Close | 22.78 |
| Employees | 7 | LT Debt/Eq | 0.07 | Earnings | Nov 05 | SMA200 | -14.47% | Avg Volume | 638.21K | Price | 22.59 |
| IPO Date | Oct 29, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 5.79% - | Net Debt/EBITDA | 2.03 | Volume | 3,316,338 | Change | -0.83% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-30-26 | Reiterated | Wedbush | Outperform | $35 → $40 |
| Jul-26-26 | Initiated | Jefferies | Buy | $50 |
| Jun-11-26 | Initiated | H.C | Buy | $45 |
| May-28-26 | Initiated | Wedbush | Outperform | $35 |
| Apr-23-26 | Initiated | RBC Capital | Outperform | $40 |
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 1 | — | — | — | — | — | |
| Gross Profit | 0 | 0 | -1 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 10 | 10 | 12 | — | — | — | — | — | |
| Research and Development | 201 | 6 | 24 | — | — | — | — | — | |
| Other Operating Expense | 0 | 1 | 0 | — | — | — | — | — | |
| Operating Income | -211 | -17 | -36 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 1 | -5 | -2 | — | — | — | — | — | |
| Net Income Before Taxes | -210 | -21 | -38 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -210 | -21 | -38 | — | — | — | — | — | |
| Net Income From Continuing Operations | -210 | -21 | -38 | — | — | — | — | — | |
| Net Income | -210 | -21 | -38 | — | — | — | — | — | |
| EPS (Recurring) | -152.99 | -18.53 | -36.08 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -152.99 | -18.53 | -36.08 | — | — | — | — | — | |
| EPS (Diluted) | -152.99 | -18.53 | -36.08 | — | — | — | — | — | |
| EBITDA | -210 | -21 | -38 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 1 | 1 | 1 | — | — | — | — | — | |
| Market Capitalization | 23 | 5 | 18 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Winslow Garrett | General Counsel | Jul 06 '26 | Sale | 29.98 | 245 | 7,345 | 2,289 | Jul 07 |
| Winslow Garrett | General Counsel | Jul 03 '26 | Option Exercise | 0.00 | 680 | 0 | 2,534 | Jul 07 |